Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease resulting in progressive cognitive decline. Amyloid plaque deposits consisting specifically of β‐amyloid peptides that have formed fibrils displaying β‐pleated sheet conformation are associated with activated microglia and astrocytes, are colocalized with C1q and other complement activation products, and appear at the time of cognitive decline in AD. Amyloid precursor protein (APP) transgenic mouse models of AD that lack the ability to activate the classical complement pathway display less neuropathology than do the APPQ+/+ mice, consistent with the hypothesis that complement activation and the resultant inflammation may play a role in the pathogenesis of AD. Further investigation of the presence of complement proteins C3 and C4 in the brain of these mice demonstrate that both C3 and C4 deposition increase with age in APPQ+/+ transgenic mice, as expected with the age‐dependent increase in fibrillar β‐amyloid deposition. In addition, while C4 is predominantly localized on the plaques and/or associated with oligodendrocytes in APPQ+/+ mice, little C4 is detected in APPQ−/− brains consistent with a lack of classical complement pathway activation because of the absence of C1q in these mice. In contrast, plaque and cell associated C3 immunoreactivity is seen in both animal models and, surprisingly, is higher in APPQ−/− than in APPQ+/+ mice, providing evidence for alternative pathway activation. The unexpected increase in C3 levels in the APPQ−/− mice coincident with decreased neuropathology provides support for the hypothesis that complement can mediate protective events as well as detrimental events in this disease. Finally, induced expression of C3 in a subset of astrocytes suggests the existence of differential activation states of these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The upregulation of mRNA for complement components in the brain with age and in neurodegenerative diseases such as AD has been documented in both human [26, 52] and mouse models [53, 54] of disease.”
From Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain (2017) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075 · cited 2×
“The importance of the balance between activation of complement and the effective regulation of the cascade in neurodegenerative disorders has been most recently evident in the association of specific single nucleotide polymorphisms in complement components C3, C2, Factor B, and Factor H, the latter a complement regula…”
BackgroundImmunoglobulins and complement factors in senile plaques: An immunoperoxidase study
Eikelenboom, P., & Stam, F. C. (1982) · Acta Neuropathologica · doi:10.1007/bf00685397 · Cited by 454
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 4×
“Interestingly, in another murine model the over-expression of an inhibitor of complement C3, Crry, resulted in increased pathology, suggesting that some complement activation fragments (such as C3b, C3a, or C5a) may decrease the neuropathology in mouse models of inflammation including those over-expressing mutant APP…”
BackgroundInfluentialVariation in complement factor 3 is associated with risk of age-related macular degeneration
Maller, J. B., Fagerness, J. A., Reynolds, R. C., Neale, B. M., Daly, M. J., & Seddon, J. M. (2007) · Nature Genetics · doi:10.1038/ng2131 · Cited by 437
Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345
Self-citationJiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., & Tenner, A. J. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.10.5050 · Cited by 330 · cited 2×
“In vitro, b-amyloid fibrils (fAb) activate both the classical complement pathway by directly binding to C1q (Rogers et al. 1992; Jiang et al. 1994) and the alternative pathway via interactions with C3 (Watson et al.”
BackgroundSelf-citation
Research works printed but not linked: 66
- Anderson D. C., 1986, Contributions of the Mac‐1 glycoprotein family to adherence‐dependent granulocyte functions: structure‐function assessments employing subunit‐specific monoclonal antibodies, J. Immunol., 137, 15, 10.4049/jimmunol.137.1.15 · doi:10.4049/jimmunol.137.1.15
- 10.1046/j.1365-2249.1999.00835.x · DOI · Paper page
- 10.4049/jimmunol.138.4.1150 · DOI · Paper page
- 10.1016/j.molimm.2006.06.021 · DOI · Paper page
- 10.4049/jimmunol.173.7.4708 · DOI · Paper page
- 10.1016/j.neulet.2005.07.015 · DOI
- 10.1084/jem.188.3.431 · DOI · Paper page
- 10.1016/S0140-6736(89)90951-3 · doi:10.1016/s0140-6736(89)90951-3
- 10.1016/S0197-4580(00)00148-2 · DOI
- 10.1016/0197-4580(96)00117-0 · DOI
- 10.1006/nlme.1996.0039 · DOI · Paper page
- Ehtesham M., 2002, The use of interleukin 12‐secreting neural stem cells for the treatment of intracranial glioma, Cancer Res., 62, 5657
- 10.1186/1742-2094-2-1 · DOI
- 10.1186/1742-2094-4-22 · DOI · Paper page
- 10.4049/jimmunol.170.11.5764 · DOI · Paper page
- 10.1189/jlb.1105683 · DOI · Paper page
- 10.1074/jbc.M605741200 · DOI · Paper page
- 10.1111/j.1432-1033.1994.tb18802.x · doi:10.1111/j.1432-1033.1994.tb18802.x
- 10.1038/nm0198-097 · DOI · Paper page
- 10.1126/science.285.5427.595 · DOI · Paper page
- 10.1016/0197-4580(92)90086-D · DOI · Paper page
- 10.1073/pnas.192203399 · DOI · Paper page
- 10.1016/S0197-4580(99)00051-2 · DOI
- 10.1089/hyb.1990.9.309 · doi:10.1089/hyb.1990.9.309
- 10.1023/A:1023203122036 · DOI
- Levi‐Strauss M., 1987, Primary cultures of murine astrocytes produce C3 and Factor B, two components of the alternative pathway of complement activation, J. Immunol., 139, 2361, 10.4049/jimmunol.139.7.2361 · DOI · Paper page
- 10.1186/1742-2094-5-9 · DOI · Paper page
- 10.1016/j.molimm.2003.10.019 · DOI
- 10.1016/S0002-9440(10)64085-0 · DOI · Paper page
- Mitchell D. A., 1999, C1q protects against the development of glomerulonephritis independently of C3 activation, J. Immunol., 162, 5676, 10.4049/jimmunol.162.10.5676 · DOI · Paper page
- 10.1016/S0169-409X(02)00162-X · DOI
- 10.1111/j.1365-2249.2004.02646.x · DOI
- 10.1016/S0165-5728(99)00261-1 · DOI
- 10.1016/S0166-2236(98)01390-3 · DOI · Paper page
- 10.4049/jimmunol.173.5.3044 · DOI · Paper page
- Ogata R. T., 1994, Substrate specificities of murine C1s, J. Immunol., 152, 5890, 10.4049/jimmunol.152.12.5890 · doi:10.4049/jimmunol.152.12.5890
- 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2 · DOI · Paper page
- 10.1006/nbdi.1996.0020 · DOI
- 10.1111/j.1471-4159.2007.05012.x · DOI · Paper page
- 10.1038/sj.emboj.7601004 · DOI · Paper page
- 10.1016/j.neulet.2005.08.022 · DOI
- 10.1073/pnas.89.21.10016 · DOI · Paper page
- 10.1074/jbc.M206448200 · DOI · Paper page
- 10.1016/0306-4522(94)90473-1 · DOI · Paper page
- Rus H. G., 1992, Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus, J. Immunol., 148, 928, 10.4049/jimmunol.148.3.928 · DOI
- 10.1080/07853890510007278 · DOI · Paper page
- 10.1016/j.jneuroim.2006.07.009 · DOI
- 10.1146/annurev.pharmtox.43.100901.140248 · DOI · Paper page
- 10.1016/j.jneuroim.2004.06.003 · DOI
- 10.1016/S0006-8993(97)00850-0 · DOI · Paper page
- 10.1007/s004010100447 · DOI
- 10.1016/S0169-328X(00)00149-2 · DOI
- 10.1007/978-0-387-73894-9_8 · DOI
- 10.1093/intimm/12.7.1015 · DOI · Paper page
- 10.1097/00001756-200102120-00022 · DOI · Paper page
- 10.1111/j.1749-6632.2003.tb03138.x · DOI · Paper page
- 10.1006/exnr.1999.7199 · DOI
- 10.1007/BF01600164 · DOI
- 10.1016/0169-328X(92)90017-6 · DOI · Paper page
- 10.3109/13506129709014379 · DOI · Paper page
- 10.1016/S0197-4580(97)00042-0 · DOI · Paper page
- 10.1096/fj.05-5814com · DOI · Paper page
- 10.1002/eji.200324026 · DOI · Paper page
- Yang L. B., 2000, Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer’s disease, J. Neurosci., 20, 7505, 10.1523/JNEUROSCI.20-20-07505.2000 · DOI · Paper page
- 10.1186/1742-2094-1-21 · DOI
- 10.1186/1742-2094-2-28 · DOI · Paper page
Cited by
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
“; (ii) in a transgenic mouse model, an increase in C3 expression coincides with a smaller degree of Aβ deposition and neuropatholog”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
Self-citationLian, H., Litvinchuk, A., Chiang, A. C.-A., Aithmitti, N., Jankowsky, J. L., & Zheng, H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2117-15.2016 · Cited by 597
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactivemicroglia (8, 9, 11, 12) and in the brains of AD amyloidosis mouse models (10, 17, 31).”
Background
Metadata
- Authors
- Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-08-11
- Volume
- 106
- Issue
- 5
- Pages
- 2080-2092
- ISSN
- 0022-3042
- 1471-4159
- Cited by
- 130
- References
- 15
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2008.05558.x
- The paper
- Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J. (2008). Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2008.05558.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.